Model of an antibody molecule

The DHVI’s Monoclonal Antibody Core Facility has a long and distinguished history of making important diagnostic and therapeutic monoclonal antibodies. Led by Dr. Haynes and Richard Scearce, the facility has made the CD44 mab, A3D8, which is being developed by NexTherapeutics, Inc. as a new generation treatment for acute myelogenous leukemia. Our investigators have made over 40 other monoclonal antibodies now marketed by 25 companies all over the world as diagnostic reagents. DHVI is currently working with Drs. Robert Clark and Ashutosh Chilkoti in the Pratt Engineering School at Duke to develop novel nanosensors as new diagnostics for infectious diseases such as HIV, Ebola, Lassa Fever, Marburg Fever, Dengue, TB and malaria. The DHVI monoclonal antibody facility currently is developing cocktails of therapeutic human neutralizing antibodies for treatment of anthrax, SARS, West Nile Virus, and Ebola hemorrhagic fever infections, among others. With the NIH Vaccine Research Center, DHVI investigators have developed new diagnostic tests for SARS and Ebola hemorrhagic fever.